MX2023002446A - Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf. - Google Patents

Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf.

Info

Publication number
MX2023002446A
MX2023002446A MX2023002446A MX2023002446A MX2023002446A MX 2023002446 A MX2023002446 A MX 2023002446A MX 2023002446 A MX2023002446 A MX 2023002446A MX 2023002446 A MX2023002446 A MX 2023002446A MX 2023002446 A MX2023002446 A MX 2023002446A
Authority
MX
Mexico
Prior art keywords
systems
methods
predicting response
tnf therapies
tnf
Prior art date
Application number
MX2023002446A
Other languages
English (en)
Inventor
Susan Ghiassian
Marc Santolini
Nancy Schoenbrunner
Keith J Johnson
Original Assignee
Scipher Medicine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipher Medicine Corp filed Critical Scipher Medicine Corp
Publication of MX2023002446A publication Critical patent/MX2023002446A/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Databases & Information Systems (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Primary Health Care (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Métodos y sistemas para administrar una terapia a sujetos que se ha determinado que no muestran una respuesta distintiva de expresión de genes establecida para distinguir entre sujetos anteriores respondedores y no respondedores que recibieron una terapia anti-TNF.
MX2023002446A 2020-09-01 2021-08-31 Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf. MX2023002446A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063073336P 2020-09-01 2020-09-01
PCT/US2021/048346 WO2022051245A2 (en) 2020-09-01 2021-08-31 Methods and systems for predicting response to anti-tnf therapies

Publications (1)

Publication Number Publication Date
MX2023002446A true MX2023002446A (es) 2023-05-12

Family

ID=80492102

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002446A MX2023002446A (es) 2020-09-01 2021-08-31 Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf.

Country Status (11)

Country Link
US (1) US20230282367A1 (es)
EP (1) EP4208256A2 (es)
JP (1) JP2023538963A (es)
KR (1) KR20240018404A (es)
CN (1) CN117615780A (es)
AU (1) AU2021336781A1 (es)
CA (1) CA3191195A1 (es)
GB (1) GB2616129A (es)
IL (1) IL300978A (es)
MX (1) MX2023002446A (es)
WO (1) WO2022051245A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
WO2020264426A1 (en) 2019-06-27 2020-12-30 Scipher Medicine Corporation Developing classifiers for stratifying patients
WO2023150731A2 (en) * 2022-02-04 2023-08-10 Scipher Medicine Corporation Systems and methods for predicting response to anti-tnf therapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092998B2 (en) * 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
EA017815B1 (ru) * 2007-06-08 2013-03-29 Байоджен Айдек Ма Инк. Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
CN102171365B (zh) * 2008-08-25 2014-01-29 森托科尔奥索生物科技公司 用于溃疡性结肠炎和相关疾病的抗tnf治疗的生物标记物
US20210325387A1 (en) * 2017-07-17 2021-10-21 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon

Also Published As

Publication number Publication date
JP2023538963A (ja) 2023-09-12
CN117615780A (zh) 2024-02-27
WO2022051245A3 (en) 2022-04-14
WO2022051245A2 (en) 2022-03-10
EP4208256A2 (en) 2023-07-12
GB2616129A (en) 2023-08-30
AU2021336781A1 (en) 2023-05-11
CA3191195A1 (en) 2022-03-10
US20230282367A1 (en) 2023-09-07
GB202303624D0 (en) 2023-04-26
IL300978A (en) 2023-04-01
KR20240018404A (ko) 2024-02-13

Similar Documents

Publication Publication Date Title
MX2023002446A (es) Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf.
Shafqat et al. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy
MX2021007816A (es) Sistemas y metodos para el manejo de fuente de gas inteligente y/o sistemas y metodos para suministro de gas terapeutico y/o verificacion de desempe?o mejorada para suministro de gas terapeutico.
Cossburn et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
MX2022000128A (es) Desarrollo de clasificadores para estratificar pacientes.
MX2021014047A (es) Metodos de diagnostico para tratamiento con linfocitos t.
Verstockt et al. Intestinal receptor of SARS-CoV-2 in inflamed IBD tissue seems downregulated by HNF4A in ileum and upregulated by interferon regulating factors in colon
EP4250302A3 (en) Methods and systems for providing therapeutic guidelines to a person having diabetes
Georganaki et al. Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
EP4285991A3 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
MX2022003962A (es) Sistema de control de glucosa en sangre.
Sebastiani et al. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register
Fink et al. Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: interim results of a phase 3 study (CLL M1 study of the German CLL Study Group)
Nguyen et al. Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis
WO2023150731A3 (en) Systems and methods for predicting response to anti-tnf therapies
Niemann et al. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)-15-month safety, response and MRD evaluation: third interim analysis from the phase II vision HO141 trial
MX2014000204A (es) Metodo de administracion y tratamiento.
Stephens et al. Interim results in clinical trials: Do we need to keep all interim randomised clinical trial results confidential?
Chatterjee et al. The Impact of ATRA on Shaping Human Myeloid Cell Responses to Epithelial Cell‐Derived Stimuli and on T‐Lymphocyte Polarization
Jelinek et al. Pre-clinical efficacy of the anti-CD38 monoclonal antibody (mAb) Isatuximab in acute myeloid leukemia (AML)
Parikh et al. A randomized phase 2 study comparing acalabrutinib with or without obinutuzumab in the treatment of early stage high risk patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Knaus et al. Acute myeloid leukemia (AML) blasts influence the gene expression signature and Co-signaling receptor expression of CD8+ T cells
Whitehill et al. Immunomodulatory effects of HDACi in combination with checkpoint blockade and lenalidomide in the immunosuppressive multiple myeloma bone marrow microenvironment
Alimam et al. Attenuated Immune Responses to the Annual Influenza A Vaccine in Patients with Myeloproliferative Neoplasms
Long et al. Tissue-Resident Memory T Cells in Allergy